Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0037315 (sleep apnea)
 8,000 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We observed nocturnal urinary protein excretion to be 16.2 +/- 5.5 micrograms/min (mean +/- SE) in 9 healthy control subjects (group I), 29.3 +/- 9.5 micrograms/min in 12 obese patients suspected to have obstructive sleep apnea syndrome (OSAS) but with negative polysomnographic studies (group II), and 94.0 +/- 31.8 micrograms/min in 14 patients with documented OSAS (group III) (II vs. I, NS; III vs. I, p less than 0.05; III vs. II, p less than 0.05). The frequency of abnormal proteinuria, defined as protein excretion greater than the highest rate observed in group I (46 micrograms/min), was 14% in group II and 64% in group III (p less than 0.05). There were no significant differences in age, body weight, body surface area, blood pressure, or indices of sleep apnea between OSAS patients with and without proteinuria. Although the mechanism is unclear, this study shows that nocturnal protein excretion rates are commonly elevated in patients with OSAS.
Nephron 1989
PMID:Nocturnal urinary protein excretion rates in patients with sleep apnea. 291 55

After the discovery of sleep apnea in 2 patients receiving chronic maintenance hemodialysis, we decided to survey all 29 male patients undergoing outpatient dialysis for symptoms suggestive of sleep apnea. 12 of 29 (41%) had positive clinical histories. 8 of these patients consented to undergo all-night polysomnography. 6 were found to have sleep apnea which was primarily obstructive in type. Recent information has implicated testosterone administration in the development of obstructive sleep apnea. Therefore, polysomnography was performed in 5 of the patients both on and off weekly testosterone injections which they were receiving to stimulate erythropoiesis. There was no change in sleep complaints or a decrease in the number of apneas and hypopneas off therapy. Sleep apnea should be considered in symptomatic male dialysis patients. Its causation is presently unknown but it does not appear to be solely related to the administration of testosterone.
Nephron 1985
PMID:Sleep apnea in hemodialysis patients: the lack of testosterone effect on its pathogenesis. 402 9

We have identified 17 obese patients (body mass index, BMI, 37.9 +/- 4.1) with proteinuria > 1 g/day (1.3-6.4 g/24 h, mean 3.1 +/- 1.7). Their age was 34-70 years (48.3 +/- 10); 11 were females and 6 males. Six patients had only one functioning kidney and a sleep apnea syndrome had been diagnosed in 5. Renal biopsies, obtained in 5 cases, showed focal glomerulosclerosis in 2 cases, minimal changes in 2 and mesangial proliferation in 1. Nine patients (group 1) were treated with hypocaloric diets; body weight significantly decreased (BMI 37.1 +/- 3, 34 +/- 3.5 and 32.6 +/- 3.2 at 0, 6 and 12 months, respectively) as well as proteinuria (2.9 +/- 1.7, 1.2 +/- 1 and 0.4 +/- 0.6 g/24 h). There was a significant correlation between body weight loss and decrease in proteinuria (r = 0.69, p < 0.05). Eight patients (group 2) were treated with captopril, without dietary changes. BMI remained stable but proteinuria showed a dramatic decrease, similar to that in group 1 (3.4 +/- 1.7, 1.2 +/- 0.9 and 0.7 +/- 1 g/24 h, respectively). Renal function remained stable in both groups. In summary, both body weight loss and captopril treatment can induce a sharp decrease in obesity-related proteinuria.
Nephron 1995
PMID:Effects of body-weight loss and captopril treatment on proteinuria associated with obesity. 761 15

A high prevalence of sleep disorders and sleep apnea syndrome in hemodialysis (HD) patients has been known for 10 years. Acetate, the buffer once most commonly used, favors intradialytic hypoxemia through hypoventilation and ventilation-perfusion changes. The aim of the present study was to assess the influence of buffer, acetate or bicarbonate, on sleep and ventilation during the night subsequent to an afternoon (2-7 p.m.) dialysis session. Ten patients, 8 males and 2 females, aged 35-71 years, dry weight 55-72 kg, on dialysis 15 h a week for 6-67 months, were randomly assigned first to acetate or bicarbonate, then to the other mode of treatment. After a series of six sessions using the same buffer, polysomnographic recordings from 9.00 p.m. to 6.00 a.m. were obtained. Sex, age, weight, data of first dialysis, blood pressure and sleep disorder-related symptoms were not correlated with the sleep apnea syndrome. Prolonged or important oxygen desaturations were never observed. Central apnea occurred more frequently during the night following acetate dialysis: x = 33 (0-180) versus 3 (0-15), p < 0.05. Obstructive apneas were not different. A defective modulation of ventilatory control after acetate HD might be held responsible for central apnea, which would constitute one more case for a widespread use of bicarbonate HD.
Nephron 1995
PMID:Sleep apnea incidence in maintenance hemodialysis patients: influence of dialysate buffer. 856 43